← All trials
NCT03526848
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 5, 2018
- Primary completion
- May 31, 2020
- Completion date
- May 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Rockefeller UniversityLead sponsor
- Rockefeller UniversityStudy chair
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Yeshiva UniversityCollaborator
- Ragon Institute of MGH, MIT and HarvardCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.